Literature DB >> 27098317

Ixekizumab: First Global Approval.

Anthony Markham1.   

Abstract

Ixekizumab (Taltz(®)) is a humanised monoclonal immunoglobulin G antibody developed by Eli Lilly and Company that has been approved in the USA as a treatment for plaque psoriasis. Ixekizumab is a specific inhibitor of interleukin-17A (IL-17A), a pro-inflammatory cytokine that has a role in the development of several inflammatory conditions. This article summarizes the milestones in the development of ixekizumab leading to this first approval for plaque psoriasis.

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27098317     DOI： 10.1007/s40265-016-0579-y

Source DB:  PubMed          Journal:  Drugs        ISSN： 0012-6667            Impact factor:   9.546


  7 in total

1.  Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials.

Authors:  Christopher E M Griffiths; Kristian Reich; Mark Lebwohl; Peter van de Kerkhof; Carle Paul; Alan Menter; Gregory S Cameron; Janelle Erickson; Lu Zhang; Roberta J Secrest; Susan Ball; Daniel K Braun; Olawale O Osuntokun; Michael P Heffernan; Brian J Nickoloff; Kim Papp
Journal:  Lancet       Date:  2015-06-10       Impact factor: 79.321

2.  Anti-interleukin-17 monoclonal antibody ixekizumab in chronic plaque psoriasis.

Authors:  Craig Leonardi; Robert Matheson; Claus Zachariae; Gregory Cameron; Linda Li; Emily Edson-Heredia; Daniel Braun; Subhashis Banerjee
Journal:  N Engl J Med       Date:  2012-03-29       Impact factor: 91.245

3.  Efficacy and safety of open-label ixekizumab treatment in Japanese patients with moderate-to-severe plaque psoriasis, erythrodermic psoriasis and generalized pustular psoriasis.

Authors:  H Saeki; H Nakagawa; T Ishii; Y Morisaki; T Aoki; P-Y Berclaz; M Heffernan
Journal:  J Eur Acad Dermatol Venereol       Date:  2014-10-30       Impact factor: 6.166

4.  IL-17A is essential for cell activation and inflammatory gene circuits in subjects with psoriasis.

Authors:  James G Krueger; Scott Fretzin; Mayte Suárez-Fariñas; Patrick A Haslett; Krista M Phipps; Gregory S Cameron; Juliet McColm; Artemis Katcherian; Inna Cueto; Traci White; Subhashis Banerjee; Robert W Hoffman
Journal:  J Allergy Clin Immunol       Date:  2012-06-05       Impact factor: 10.793

5.  A 52-week, open-label study of the efficacy and safety of ixekizumab, an anti-interleukin-17A monoclonal antibody, in patients with chronic plaque psoriasis.

Authors:  Kenneth B Gordon; Craig L Leonardi; Mark Lebwohl; Andrew Blauvelt; Gregory S Cameron; Daniel Braun; Janelle Erickson; Michael Heffernan
Journal:  J Am Acad Dermatol       Date:  2014-09-19       Impact factor: 11.527

6.  A phase II randomized study of subcutaneous ixekizumab, an anti-interleukin-17 monoclonal antibody, in rheumatoid arthritis patients who were naive to biologic agents or had an inadequate response to tumor necrosis factor inhibitors.

Authors:  Mark C Genovese; Maria Greenwald; Chul-Soo Cho; Alberto Berman; Ling Jin; Gregory S Cameron; Olivier Benichou; Li Xie; Daniel Braun; Pierre-Yves Berclaz; Subhashis Banerjee
Journal:  Arthritis Rheumatol       Date:  2014-07       Impact factor: 10.995

7.  Safety and Efficacy of Open-label Subcutaneous Ixekizumab Treatment for 48 Weeks in a Phase II Study in Biologic-naive and TNF-IR Patients with Rheumatoid Arthritis.

Authors:  Mark C Genovese; Daniel K Braun; Janelle S Erickson; Pierre-Yves Berclaz; Subhashis Banerjee; Michael P Heffernan; Hilde Carlier
Journal:  J Rheumatol       Date:  2015-12-15       Impact factor: 4.666
  7 in total
  5 in total

1.  Development of tibulizumab, a tetravalent bispecific antibody targeting BAFF and IL-17A for the treatment of autoimmune disease.

Authors:  Robert J Benschop; Chi-Kin Chow; Yu Tian; James Nelson; Barbra Barmettler; Shane Atwell; David Clawson; Qing Chai; Bryan Jones; Jon Fitchett; Stacy Torgerson; Yan Ji; Holly Bina; Ningjie Hu; Mahmoud Ghanem; Joseph Manetta; Victor J Wroblewski; Jirong Lu; Barrett W Allan
Journal:  MAbs       Date:  2019-06-10       Impact factor: 5.857

Review 2.  Mucocutaneous IL-17 immunity in mice and humans: host defense vs. excessive inflammation.

Authors:  J Li; J-L Casanova; A Puel
Journal:  Mucosal Immunol       Date:  2017-11-29       Impact factor: 7.313

Review 3.  Phage Display Technology as a Powerful Platform for Antibody Drug Discovery.

Authors:  Kazuya Nagano; Yasuo Tsutsumi
Journal:  Viruses       Date:  2021-01-25       Impact factor: 5.048

Review 4.  Application of recombinant antibodies for treatment of Clostridioides difficile infection: Current status and future perspective.

Authors:  Hamideh Raeisi; Masoumeh Azimirad; Ali Nabavi-Rad; Hamid Asadzadeh Aghdaei; Abbas Yadegar; Mohammad Reza Zali
Journal:  Front Immunol       Date:  2022-08-23       Impact factor: 8.786

Review 5.  Interleukin-17 as a potential therapeutic target for chronic pain.

Authors:  Xiaojuan Jiang; Ruihao Zhou; Yujun Zhang; Tao Zhu; Qian Li; Weiyi Zhang
Journal:  Front Immunol       Date:  2022-09-29       Impact factor: 8.786
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.